Clinical potential of photodynamic therapy in cardiovascular disorders

被引：30

作者：

Kossodo S. ^{[1
]}

LaMuraglia G.M. ^{[1
]}

机构：

[1] Division of Vascular Surgery, Department of Surgery and Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Boston

来源：

American Journal of Cardiovascular Drugs | 2001年 / 1卷 / 1期

关键词：

Methylene Blue; Intimal Hyperplasia; Verteporfin; Photofrin; Tranilast;

D O I：

10.2165/00129784-200101010-00002

中图分类号：

学科分类号：

摘要：

Atherosclerosis and intimal hyperplasia remain obstacles for surgeons to overcome following vascular reconstructions. Even with all of the technical improvements that have occurred in the past several decades, long term patency following intervention is hindered by these inherent adverse developments. Today, the use of light is seen as a potential treatment modality in vascular surgery. Photodynamic therapy (PDT) has been used in the treatment of cancer, and because of its continued success in vascular experimental models it is now being tested in clinical trials for vascular diseases. PDT offers the surgeon many advantages, and it may have unlimited uses in the clinical setting. Is PDT the ultimate treatment modality for the cardiovascular surgeon and will it help to overcome the inherent failures associated with vascular reconstructions? It may be too early to answer these questions, but with the current successes demonstrated by PDT, there is a need for further testing in clinical trials. In the near uture, PDT may be used clinically as a treatment modality to inhibit restenosis and intimal hyperplasia following surgical intervention. © Adis International Limited. All rights reserved.

引用

页码：15 / 21

页数：6

共 79 条

[1] National Center for Chronic Disease Prevention and Health Promotion. Cardiovascular Diseases, 14, (2000)
[2] Schwartz R.S., Topol E.J., Serruys P.W., Et al., Artery size, neointima, and remodeling: Time for some standards, J Am Coll Cardiol, 32, 7, pp. 2087-2094, (1998)
[3] Serruys P.W., De Jaegere P., Kiemeneij F., Et al., A comparison of balloonexpandable- stent implantation with balloon angioplasty in patients with coronary artery disease, N Engl J Med, 331, 8, pp. 489-495, (1994)
[4] Topol E.J., Califf R.M., Weisman H.F., Et al., Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months, Lancet, 8902, 343, pp. 881-886, (1994)
[5] Maresta A., Balducelli M., Cantini L., Et al., Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: Results of the randomized, doubleblind STARC study Studio Trapidil versus Aspirin nella Restenosi Coronarica, Circulation, 90, 6, pp. 2710-2715, (1994)
[6] Cote G., Tardif J.C., Lesperance J., Et al., Multivitamins and Protocol Study Group Effects of probucol on vascular remodeling after coronary angioplasty, Circulation, 99, 1, pp. 30-35, (1999)
[7] Raizner A.E., Oesterle S.N., Waksman R., Et al., Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT), Circulation, 102, 9, pp. 951-958, (2000)
[8] Tamai H., Katoh O., Suzuki S., Et al., Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT), Am Heart J, 138, 5, pp. 968-975, (1999)
[9] Smith R.C., Walsh K., Gene therapy for restenosis, Curr Cardiol Rep, 2, 1, pp. 13-23, (2000)
[10] Teirstein P.S., Massullo V., Jani S., Et al., Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis, Circulation, 99, 2, pp. 243-247, (1999)

← 1 2 3 4 5 6 7 8 →